### Comment:
Remember that the pharmaceutical and biotechnology industry suffers from the ‘its the only thing we have’ phenomenon, it’s the only dual SGLT inhibitor in existence, and its also going to be the first type 1 diabetes treatment proposed in more than a decade; its only competition is primlantide. Also, there are no scams here, as insider ownership isn’t even 4%; the ‘people’ are deciding efficacy here.

### REPLY:
Yeah sure everything you said is right but that doesn’t discount that if the fda votes to reject the stock will plummet. It’s a very risky play. In the biopharma world, playing clinical data releases is what everyone does because of the minimized risk. But FDA results are another story. You’re accepting a chance of 80%+ drop if they aren’t successful.

### END.